All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

AstraZeneca’s Imfinzi nabs FDA approval for lung cancer in perioperative setting
Monoclonal antibody, lung cancer - Read more

Vericel’s NexoBrid lands FDA approval for pediatric burns
Proteolytic enzyme, eschar removal, burns - Read more

Cresilon’s bloodstopping hydrogel applicator lands FDA 510(k) clearance
Hydrogel, medical device, bleeding - Read more

THE GOOD
Clinical Trials

Incyte’s positive Ph3 Monjuvi+combo lymphoma data to spur supplemental BLA push later this year
Monoclonal antibody, combo therapy, lymphoma, cancer - Read more

THE GOOD
Fundraises

Immuron AUD$3.5M ($2.3M) research award from US DoD
Bovine colostrum, endemic military relevant diarrheal pathogen, traveller’s diarrhea - Read more

Neptune Medical $97M raise, launches Jupiter Endovascular
Medical device, catheter-based therapy, blood clot removal - Read more

THE GOOD
Investments

Novo Nordisk to invest DKK1.5B ($221 million) in new Pharmatech division site
Manufacturing, raw materials - Read more

THE GOOD
Lawsuits

GSK nabs another Zantac lawsuit win, this time in Florida
Small molecule, heartburn, cancer - Read more

THE GOOD
Mergers & Acquisitions

From PE to PE firm, as Blackstone agrees to buy healthcare consultancy Chartis Group from Audax Private Equity
Healthcare consulting - Read more

At the same time, Audax Private Equity buys Avantor’s CRO business for $650M
CRO, clinical research services - Read more

PRESENTED BY THE UBC SCHOOL OF BIOMEDICAL ENGINEERING
Unlock the Future of Healthcare Innovation

Join us online on Wednesday, September 25th, at 5:30 PM Pacific for an information session about UBC's new Micro-certificate in Innovation Leadership: Medical & Bio-Innovations.

Discover how this transformative program equips you with essential legal, strategic, and practical skills to bridge the gap between scientific breakthroughs and market success.

What to Expect:

• Learn about the unique opportunities this program offers to advance your career.

• Understand how to make a meaningful impact on healthcare.

• Participate in a live Q&A session.

Don’t miss this opportunity—register now to secure your spot!🔗 

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Partnerships

EnPlusOne Biosciences, Wyss Institute up to $27M RNA drug development platform collab
RNA, drug development, cancer, infectious disease - Read more

THE GOOD
Public Health

Gavi vaccine group says they have $500M to supply shots to mpox-afflicted low- and middle-income countries
Vaccine, infectious disease, monkeypox (mpox) - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trals

Pfizer, BioNTech combo COVID-19/flu shot misses a primary endpoint in Ph3, doesn’t perform well against influenza A and B
mRNA vaccine, COVID-19, influenza - Read more

THE BAD
Earnings & Finances

AN2 Therapeutics adopts a “poison pill” strategy against potential stock-driven takeover
Small molecule, chagas disease, nontuberculous mycobacteria (NTM), and melioidosis - Read more

THE BAD
Strategic Plans

Genentech (Roche) shutters separate cancer immunology research department, merges with molecular oncology research
Cancer research, drug discovery & development - Read more

THE UGLY
Patient Access

Access to Novo Nordisk’s Wegovy for older American’s with heart disease is increasingly difficult (if not impossible); physician survey
GLP-1, obesity, heart disease - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.